Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

被引：0
|
作者：
Cohen, Stanley [1 ]
Czeloth, Niklas [2 ]
Lees, Eric [3 ]
Klimiuk, Piotr A. [4 ,5 ]
Peter, Nuala [6 ]
Jayadeva, Girish [2 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Inland Rheumatol, Upland, CA USA
[4] Med Univ Bialystok, Bialystok, Poland
[5] Gabinet Internistyczno Reumatol, Bialystok, Poland
[6] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2522
引用
收藏
页数：2
相关论文
共 50 条
  • [21] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY
    Fleischmann, R.
    Mysler, E.
    Bessette, L.
    Peterfy, C.
    Durez, P.
    Tanaka, Y.
    Swierkot, J.
    Khan, N.
    Bu, X.
    Li, Y.
    Song, I. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 251 - 252
  • [22] Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1708 - 1710
  • [23] Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study
    Brunner, Hermine I.
    Ruperto, Nicolino
    Quartier, Pierre
    Constantin', Tamas
    Alexeeva, Ekaterina
    Kone-Paut, Isabelle
    Marzan, Katherine
    Wulffraat, Nico
    Schneider, Rayfel
    Padeh, Shai
    Chasnyk, Vyacheslav
    Wouters, Carine
    Kuemmerle-Deschner, Jasmin B.
    Kallinich, Tilmann
    Lauwerys, Bernard
    Haddad, Elie
    Nasonov, Evgeny L.
    Trachana, Maria
    Vougiouka, Olga
    Leon, Karolynn
    Vritzali, Eleni
    Lheritier, Karine
    Martinis, Alberto
    Lovell, Daniel J.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [24] Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
    Sandborn, William J.
    Feagan, Brian G.
    Hanauer, Stephen
    Vermeire, Severine
    Ghosh, Subrata
    Liu, Wenzhong J.
    Petersen, AnnKatrin
    Charles, Lorna
    Huang, Vivian
    Usiskin, Keith
    Wolf, Douglas C.
    D'Haens, Geert
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (07): : 1120 - 1129
  • [25] BARICITINIB, METHOTREXATE, OR BARICITINIB PLUS METHOTREXATE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD RECEIVED LIMITED OR NO TREATMENT WITH DMARDS: EFFICACY AND SAFETY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEGIN STUDY
    Durez, Patrick
    Walker, David
    Geusens, Piet
    Van den Bosch, Filip
    Shaikh, Saeed
    Roccatello, Dario
    Tahir, Hasan
    Zamani, Omid
    Stoykov, Ivaylo
    Otawa, Susan
    Rogai, Veronica
    Larsson, Esbjorn
    Holzkaemper, Thorsten
    Arthanari, Subhashini
    Pum, Georg
    Leage, Soyi Liu
    Gjertsson, Inger
    Puttini, Piercarlo Sarzi
    Kekow, Joern
    De La Torre, Inmaculada
    RHEUMATOLOGY, 2017, 56 : 134 - 135
  • [26] Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles G.
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    RMD OPEN, 2022, 8 (01):
  • [27] Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
    Genovese, Mark C.
    Kellner, Herbert
    Arai, Yasumasa
    Muniz, Rafael
    Alten, Rieke
    RMD OPEN, 2020, 6 (01):
  • [28] EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB (REFADL) TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA)
    Wiland, Piotr
    Jeka, Slawomir
    Dokoupilova, Eva
    Miranda Limon, Juan Manuel
    Jauch-Lembach, Julia
    Thakur, Anjali
    Haliduola, Halimuniyazi
    Gaylis, Norman
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 706 - 707
  • [29] Efficacy and Safety of Upadacitinib Maintenance Treatment in Patients With Moderately to Severely Active Crohn's Disease: Two Year Results From the U-ENDURE Long-Term Extension Study
    D'Haens, Geert R.
    Louis, Edouard
    Loftus, Edward V.
    Regueiro, Miguel D.
    Jairath, Vipul
    Magro, Fernando
    Nakase, Hiroshi
    Dubcenco, Elena
    Lacerda, Ana Paula
    Feng, Tian
    Duncan, Benjamin
    Wang, Tao
    Anyanwu, Samuel
    Aponte, Fernando
    Blumenstein, Irina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S737 - S739
  • [30] Long-Term Efficacy, Safety and Immunogenicity Results from a Randomized, Double-Blind, Phase III Confirmatory Efficacy and Safety Study Comparing GP2017, a Proposed Biosimilar, with Reference Adalimumab
    Blauvelt, Andrew
    Lacour, Jean-Phillipe
    Fowler, Joseph
    Schuck, Ellen
    Jauch-Lembach, Julia
    Balfour, Alison
    Leonardi, Craig
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345